Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of JNJ-69095897 in healthy participants
NL-OMON52349Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in affective disorder comparing JNJ-69095897 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics of JNJ-69095897. Started Jun 2021; status: active, not recruiting.
02
Drugs
JNJ-69095897
03
Conditions
affective disorder
Beyond the preview
Go deeper on NL-OMON52349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52349.